Bolt Biotherapeutics (NASDAQ:BOLT) Lowered to Hold Rating by Zacks Research

Zacks Research cut shares of Bolt Biotherapeutics (NASDAQ:BOLT) from a strong-buy rating to a hold rating in a research report report published on Thursday morning,Zacks.com reports.

A number of other equities research analysts have also weighed in on BOLT. Lake Street Capital raised their price objective on Bolt Biotherapeutics to $75.00 and gave the company a “buy” rating in a research note on Friday, August 15th. HC Wainwright set a $7.00 price target on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Down 1.2%

Bolt Biotherapeutics stock traded down $0.06 during midday trading on Thursday, hitting $4.74. 10,180 shares of the stock were exchanged, compared to its average volume of 38,261. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $13.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The firm has a market cap of $9.10 million, a P/E ratio of -0.21 and a beta of 0.93. The company has a 50 day moving average price of $5.39 and a two-hundred day moving average price of $5.71.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.07) by $1.35. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $0.82 million. On average, sell-side analysts predict that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC increased its stake in Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $85,000. Finally, Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics during the third quarter worth about $89,000. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.